Infectious Disease · AntibioticRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for NUZYRA (Omadacycline Tosylate)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/16/2026, 12:33:18 AM

Assessment confidence: 54% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's acceptance of the supplemental application for NUZYRA signals potential label expansion, which could significantly impact PARATEK's competitive positioning in the antibiotic market. Portfolio teams should closely monitor this development as it may influence market dynamics and share. Regulatory context from FDA (FDA AP — NUZYRA (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of NUZYRA's expanded indications on market share and competitive dynamics. The strongest clinical anchor is Genetic Studies of Chronic Active Epstein-Barr Disease (ClinicalTrials.gov), moderate corpus alignment. In Infectious Disease · Antibiotic, 7 regulatory and 3 competitive items passed relevance filtering for PARATEK PHARMS.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Grants Priority Review for VYVGART Supplement Application. This acceptance may enhance PARATEK's position in the antibiotic market, especially against competitors in the same therapeutic area.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — NUZYRA (SUPPL) (FDA). Entity match (paratek pharms). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and any label changes will be crucial for market strategy.

Key Risks

Elevated medium regulatory exposure for PARATEK PHARMS could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, the expanded indications for NUZYRA could enhance PARATEK's market share and revenue potential, particularly in a competitive landscape where antibiotic options are critical.
Upside for PARATEK PHARMS may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Lead sponsor: Bausch & Lomb Incorporated.
Portfolio teams should assess the potential impact of NUZYRA's expanded indications on market share and competitive dynamics.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the review process and any subsequent approvals or label changes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — NUZYRA (SUPPL)
FDAhigh relevance
Entity match (paratek pharms)
FDA document
View source
FDA AP — LITFULO (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
FDAhigh relevance
Regulatory pathway relevance (supplement)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — FETROJA (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Genetic Studies of Chronic Active Epstein-Barr Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety and Efficacy of Fixed-Dose Combination for Dry Eye Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for VYVGART Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Lactiplantibacillus plantarum (WJL) ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Compliance with preoperative antibiotic prophylaxis in cesarean delivery and its impact on surgical site infections: A national retrospective study of Jordan.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

PARATEK PHARMS
NUZYRA

Commercial impact

medium

If approved, the expanded indications for NUZYRA could enhance PARATEK's market share and revenue potential, particularly in a competitive landscape where antibiotic options are critical.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and any label changes will be crucial for market strategy.

What to watch

Monitor for further updates on the review process and any subsequent approvals or label changes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.